drugset
Drugs / FTC/TAF
last change May 2023 re-read 9 days ago

FTC/TAF

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 2 NCT04493216 Background Nov 2020 → Sep 2022 HIV infectious disease ViiV Healthcare Terminated No outcome recorded Stop: Business

Press releases naming this drug 1 release

DateIssuerRelease
2023-02-23 ViiV Healthcare ViiV HEALTHCARE ANNOUNCES POSITIVE DATA DEMONSTRATING LONG-ACTING INJECTABLE CABENUVA (CABOTEGRAVIR, RILPIVIRINE) IS AS EFFECTIVE AS DAILY ORAL BIKTARVY (BIC/FTC/TAF) FOR THE TREATMENT OF HIV-1 viivhealthcare.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as FTC/TAF ClinicalTrials.gov intervention name — accepted as the source's own label NCT04493216 ↗
Route Oral “FTC/TAF was available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.” NCT04493216 ↗